

Resource Summary Report

Generated by PRECISE-TBI on Sep 8, 2026

Treat-NMD

RRID:SCR_006612

Type: Tool

Proper Citation

Treat-NMD (RRID:SCR_006612)

Resource Information

URL: <http://www.treat-nmd.eu/>

Proper Citation: Treat-NMD (RRID:SCR_006612)

Description: TREAT-NMD is a network for the neuromuscular field that is creating the infrastructure to ensure that the most promising new therapies reach patients as quickly as possible. Since its launch in January 2007 the network's focus has been on the development of tools that industry, clinicians and scientists need to bring novel therapeutic approaches through preclinical development and into the clinic, and on establishing best-practice care for neuromuscular patients worldwide.

Synonyms: Treat-NMD Neuromuscular Network, TreatNMD

Resource Type: data or information resource, disease-related portal, portal, topical portal

Keywords: neuromuscular disease, muscular dystrophy, spinal muscular atrophy

Funding: Priority 1 Life Sciences ;
Genomics and Biotechnology for Health of the European Union FP6 LSHM-CT-2006-036825

Resource Name: Treat-NMD

Resource ID: SCR_006612

Alternate IDs: nif-0000-06711

Record Creation Time: 20220129T080237+0000

Record Last Update: 20260905T132557+0000

Ratings and Alerts

No rating or validation information has been found for Treat-NMD.

No alerts have been found for Treat-NMD.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 70 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Ait-Lounis A, et al. (2025) Persistent tissue regeneration and transforming growth factor- β induced fibrosis in the masseter muscle of mdx5Cv mice. Scientific reports, 15(1), 33503.

Vogt G, et al. (2021) Expanding the clinical and molecular spectrum of ATP6V1A related metabolic cutis laxa. Journal of inherited metabolic disease, 44(4), 972.

Geist Hauserman J, et al. (2021) Sarcomeric deficits underlie MYBPC1-associated myopathy with myogenic tremor. JCI insight, 6(19).

Lusakowska A, et al. (2021) Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy. Orphanet journal of rare diseases, 16(1), 150.

Rossi R, et al. (2021) Circadian Genes as Exploratory Biomarkers in DMD: Results From Both the mdx Mouse Model and Patients. Frontiers in physiology, 12, 678974.

Zhou H, et al. (2020) Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. Journal of cachexia, sarcopenia and muscle, 11(3), 768.

Godefroy A, et al. (2019) Mannose 6-phosphonate labelling: A key for processing the therapeutic enzyme in Pompe disease. Journal of cellular and molecular medicine, 23(9), 6499.

Jumah MA, et al. (2019) Current management of Duchenne muscular dystrophy in the Middle East: expert report. Neurodegenerative disease management, 9(3), 123.

Guiraud S, et al. (2019) The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. Human molecular genetics, 28(13), 2189.

Pogoryelova O, et al. (2018) Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: First report from the GNE myopathy Disease Monitoring Program, registry portion. Neuromuscular disorders : NMD, 28(2), 158.

Yoon S, et al. (2018) Aberrant Caspase Activation in Laminin- α 2-Deficient Human Myogenic Cells is Mediated by p53 and Sirtuin Activity. *Journal of neuromuscular diseases*, 5(1), 59.

Morís G, et al. (2018) Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy. *Muscle & nerve*, 57(3), 380.

Capogrosso RF, et al. (2018) Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 32(2), 1025.

Guien C, et al. (2018) The French National Registry of patients with Facioscapulohumeral muscular dystrophy. *Orphanet journal of rare diseases*, 13(1), 218.

Verhaart IEC, et al. (2017) A multi-source approach to determine SMA incidence and research ready population. *Journal of neurology*, 264(7), 1465.

Shabanpoor F, et al. (2017) Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy. *Nucleic acid therapeutics*, 27(3), 130.

Ryder S, et al. (2017) The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. *Orphanet journal of rare diseases*, 12(1), 79.

Walter MC, et al. (2017) Recent developments in Duchenne muscular dystrophy: facts and numbers. *Journal of cachexia, sarcopenia and muscle*, 8(5), 681.

Fontes-Oliveira CC, et al. (2017) Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells. *Scientific reports*, 7, 45272.

Robin V, et al. (2017) Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment. *Molecular therapy. Nucleic acids*, 7, 81.